Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 5 |
List of Tables | 4 | 2 |
List of Figures | 6 | 1 |
Alere Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 | 6 | 2 |
Alere Inc., Medical Equipment Deals By Type, 2010 to YTD 2016 | 8 | 1 |
Alere Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 | 9 | 1 |
Alere Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016 | 10 | 1 |
Alere Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 | 11 | 3 |
Alere Inc., Medical Equipment, Deal Details | 14 | 52 |
Private Equity | 14 | 1 |
Pharos Capital Group Acquires Majority Stake in TechLab | 14 | 2 |
Exponent Private Equity Acquires BBI Diagnostics from Alere for USD162 Million | 16 | 1 |
Partnerships | 17 | 1 |
Axis-Shield Enters into Licensing Agreement with Hangzhou Joinstar Biomedical | 17 | 1 |
Axis-Shield Diagnostic Enters into Licensing Agreement with Siemens Healthcare Diagnostics | 18 | 1 |
Alere Exercises Option For Licensing Agreement With Miraculins For Endoglin Products | 19 | 1 |
VitaPath Genetics Enters Into Licensing Agreement With Alere | 20 | 1 |
Thermo Fisher Scientific Enters Into Licensing Agreement With Alere | 21 | 1 |
Alere Enters Into Licensing Agreement With Roche Diagnostics | 22 | 1 |
Roche Diagnostics Enters Into Licensing Agreement With Alere | 23 | 1 |
Chembio Terminates Distribution Agreement With Alere | 24 | 1 |
Alere Enters Into Co-Development Agreement With AT&T | 25 | 1 |
EKF Diagnostics Enters Into Distribution Agreement With Alere | 26 | 1 |
Spartan Bioscience Enters Into Distribution Agreement With Alere | 27 | 1 |
Systagenix Wound Management Enters Into Co-Development Agreement With Alere | 28 | 1 |
Laboratorios Rubio Enters Into Distribution Agreement With Alere Healthcare | 29 | 1 |
AnaSpec Enters Into Distribution Agreement With Bioeasy Diagnostica | 30 | 1 |
BG Medicine Enters Into An Agreement With Inverness Medical Innovations | 31 | 1 |
FIND Enters Into Agreement With Standard Diagnostics | 32 | 1 |
Miraculins Enters Into An Agreement With Inverness Medical Innovations | 33 | 1 |
Inverness Medical Innovations Enters Into Distribution Agreement With Epocal | 34 | 1 |
AdnaGen Extends Licensing Agreement With KellBenx | 35 | 1 |
Debt Offering | 36 | 1 |
Alere Raises USD425 Million in Private Placement of 6.37% Notes Due 2023 | 36 | 1 |
Alere Completes Private Placement Of Notes Due 2020 For US$425 Million | 37 | 2 |
Alere Completes Private Placement Of Notes Due 2018 For US$450 Million | 39 | 2 |
Alere Completes Private Placement Of Senior Subordinate Notes For US$400 Million | 41 | 1 |
Asset Transactions | 42 | 1 |
QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen | 42 | 1 |
Coppersmith Capital Management Reportedly Wants Alere To Explore Sale Of Its Drug Testing And Toxicology Businesses For Up To US$5 Billion | 43 | 1 |
Acquisition | 44 | 1 |
Abbott Labs to Acquire Alere | 44 | 2 |
Alere Acquires US Diagnostics USD60 Million | 46 | 1 |
Ron Zwanziger Plans to Acquire Alere for USD3.82 Billion | 47 | 1 |
Alere Completes Acquisition Of Epocal For Up To US$241 Million | 48 | 2 |
Alere Acquires eScreen for USD296 Million | 50 | 2 |
Arriva Medical Acquires AmMed Direct For US$23 Million | 52 | 1 |
Arriva Medical Acquires Direct Diabetic Source | 53 | 1 |
Alere Completes Acquisition Of Medical Automation System | 54 | 1 |
Alere Acquires Arriva Medical From Palm Beach Capital For US$83 Million | 55 | 1 |
Alere Completes Acquisition Of Axis-Shield, Diagnostic Test Maker, For US$389 Million | 56 | 2 |
Alere Acquires Lab Data Systems | 58 | 1 |
Alere Holdings Bermuda Acquires 78% Stake Of AdnaGen From OncoVista Innovative Therapies | 59 | 2 |
EKF Diagnostics Acquires Quotient Diagnostics | 61 | 2 |
Inverness Medical Innovations Acquires 78.13% Stake In Standard Diagnostics | 63 | 2 |
Inverness Medical Innovations To Acquire Kroll Lab Specialists From Kroll | 65 | 1 |
Alere Inc. - Key Competitors | 66 | 1 |
Key Employees | 67 | 2 |
Locations And Subsidiaries | 69 | 7 |
Head Office | 69 | 1 |
Other Locations &Subsidiaries | 69 | 7 |
Recent Developments | 76 | 1 |
Financial Announcements | 76 | 1 |
Sep 06, 2016: Alere Reports Second Quarter 2016 Financial Results | 76 | 1 |
Aug 17, 2016: Alere Reports First Quarter 2016 Financial Results | 77 | 1 |
Aug 08, 2016: Alere Files Form 10-K, Reports Fourth Quarter and Full Year 2015 Financial Results | 78 | 2 |
Nov 04, 2015: Alere Reports Third Quarter 2015 Financial Results | 80 | 2 |
May 05, 2015: Alere Reports Preliminary First Quarter 2015 Financial Results and Announces 2014 Restatement | 82 | 1 |
Feb 10, 2015: Alere Announces Fourth Quarter 2014 Results | 83 | 2 |
Corporate Communications | 85 | 1 |
Jul 23, 2015: Dr. Geoffrey S. Ginsburg Joins Alere Board | 85 | 1 |
Mar 09, 2015: Alere Announces Chief Financial Officer Transition | 86 | 1 |
Legal and Regulatory | 87 | 1 |
Oct 15, 2015: Alere Receives U.S. HHS Approval to Electronically Process Drug Tests for Department of Transportation-Regulated Employees | 87 | 1 |
Product News | 88 | 1 |
Mar 18, 2016: Alere Comments on Alere Anticoagulation Monitoring Technology | 88 | 1 |
Jul 16, 2015: Alere Receives FDA CLIA Waiver for Alere i Strep A Rapid Molecular Test | 89 | 1 |
Apr 02, 2015: Alere Receives FDA Clearance for Alere i Strep A Rapid Molecular Test | 90 | 1 |
Mar 02, 2015: Alere Receives IVD CE Mark for Alere q HIV-1/2 Detect Assay for Molecular Diagnosis of HIV at the Point of Care | 91 | 1 |
Jan 07, 2015: Alere Receives FDA CLIA Waiver for Alere i Influenza A &B Test | 92 | 1 |
Jan 06, 2015: FDA grants first CLIA waiver for nucleic acid-based flu diagnostic test | 93 | 1 |
Product Approvals | 94 | 1 |
Apr 02, 2015: Alere Receives FDA Clearance for Alere i Strep A Rapid Molecular Test | 94 | 1 |
Mar 02, 2015: Alere Receives IVD CE Mark for Alere q HIV-1/2 Detect Assay for Molecular Diagnosis of HIV at the Point of Care | 95 | 1 |
Jan 06, 2015: FDA grants first CLIA waiver for nucleic acid-based flu diagnostic test | 96 | 1 |
Other Significant Developments | 97 | 1 |
Jun 10, 2015: New Approach on HIV Viral Load Testing | 97 | 1 |
Appendix | 98 | 1 |
Methodology | 98 | 1 |
About GlobalData | 98 | 1 |
Contact Us | 98 | 1 |
Disclaimer | 98 | 1 |